Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?Immunology Published on 2020-05-282022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, [키워드] “cytokine storm” absence airway anti-inflammatory drug Anti-viral clinical trial complementary complications of COVID-19 coronavirus disease COVID-19 COVID-19 patient Cytokine storm drug Drug repurposing effective Effectiveness Efficacy and safety Efficiency Evidence exaggerated inflammatory response FDA approval Health inflammatory complication lack lung lung injuries Lung injury Multiple myeloma occur offer outcome pandemic Patient positive progression pulmonary diseases Registered respiratory complication subsequent thalidomide treated Vaccine victim viral infection [DOI] 10.3389/fimmu.2020.01248 PMC 바로가기 [Article Type] Immunology
Pathological Role of Angiotensin II in Severe COVID-19Review Article Published on 2020-04-262022-10-29 Journal: TH Open: Companion Journal to Thrombosis and Haemostasis [Category] COVID-19, [키워드] activated Activation acute respiratory distress angiotensin Angiotensin II angiotensin-converting enzyme 2 caused characterized clinical picture Coagulation Coagulopathy complex COVID-19 COVID-19 patients death downregulating Effect Elderly patient exaggerated inflammatory response expressed Future impair increase increasingly induce Inflammation inflammatory property Lung injury manifestation new coronavirus SARS-CoV-2 Novel coronavirus infection pathological Patient patients preexisting comorbidities produced proportion prothrombotic state receptor reduced renin–angiotensin system resulting role SARS-CoV-2 Sepsis severe complication severe COVID-19 syndrome target cells thrombin Treatment triggered Viral load [DOI] 10.1055/s-0040-1713678 PMC 바로가기 [Article Type] Review Article